Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Lee’s Pharma and Partners Plan Global Phase III trial of Cancer Immunotherapy

publication date: Mar 27, 2014
Lee’s Pharma of Hong Kong, together with partners Transgene SA and SillaJen, plans to start a global Phase III trial of Pexa-Vec, an immunotherapy for cancer, as a first-line treatment for liver cancer during mid-2015. Because Pexa-Vec did not meet its endpoints in a recent Phase II trial, the drug’s future was in doubt. Lee’s owns China rights to Pexa-Vec. Transgene, a listed subsidiary of France’s Institute Merieux, has rights in Europe and the Middle East. SillaJen, a South Korean CRO, recently paid $150 million to acquire Jennerex, which developed Pexa-Vec. More details....

Stock Symbols: (HK: 0950) (PA: TNG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital